Audited Supplier
In This Store
Focus on natural origin and oncology APIs, setting up R&D and production platform for new salt and crystal form, deep cooperation with clients for IND, NDA, ANDA, 505b(2) or P-IV challenge.
Explore the potential of macromolecular APIs, setting up R&D and production platform for Glycans and polypeptide.
Specialized in XDC drugs field, committed to platform building for the innovative research and production on payload and Best-Link.
Global registration platform, professional team, and international cGMP system.
API CDMO service with global registration.
Strategy: FDF + APIs.
Tel: +86-28-17360040767
Website: www.xielipharm.com.cn、www.elixir-pharm.com
Year of Establishment: 2021
Total Assets(USD): More than 99,999,999
Total Number of Staff: 10-50
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Small Orders Accepted,Quality Service
Other Competitive Advantages: R&D Team （1）Stable R&D team with over 10 years of experience, more than 20 successful R&D projects. （2）Synthesis Lab with GRLP standard. （3）Analysis Lab in accordance with GMP conditions. （4）In collaboration with well-known universities, focus on new salt, new crystal form and novel technologies, such as synthetic biology and continuous-flow synthetic.
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go
